Sialyl Tn-expressing bladder cancer cells induce a tolerogenic phenotype in innate and adaptive immune cells

Molecular Oncology

Volumn 8, Issue 3, 2014, Pages 753-765

  Carrascal, Mylène A ^a   Severino, Paulo F ^a,b   Guadalupe Cabral, M ^a,c   Silva, Mariana ^a   Ferreira, José Alexandre ^d,e   Calais, Fernando ^f   Quinto, Hermínia ^f   Pen, Cláudia ^f   Ligeiro, Dário ^g   Santos, Lúcio Lara ^e   Dall'Olio, Fabio ^b   Videira, Paula A ^a  

^a NOVA MEDICAL SCHOOL   (Portugal)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSIDADE LUSÓFONA DE HUMANIDADES E TECNOLOGIAS   (Portugal)

^d UNIVERSITY OF AVEIRO   (Portugal)

^e PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^f EPE Serviço de Anatomia Patológica ^*  (Portugal)

^g Ministerio da Saude Portuguese   (Portugal)

Author keywords

CD44; Dendritic cells; Immunological potency; Mucins; Sialyl Tn; T cells

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; CYTOKINE; GLYCAN; GLYCOPROTEIN; HERMES ANTIGEN; INTERLEUKIN 12; MUCIN 1; SIALYL TN ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; SIALOSYL-TN ANTIGEN; TUMOR ANTIGEN;

ADAPTIVE IMMUNITY; ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER CELL; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IN VITRO STUDY; INNATE IMMUNITY; MALE; MIDDLE AGED; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; VERY ELDERLY; BLADDER; BLADDER TUMOR; CELL CULTURE; IMMUNOLOGY; PATHOLOGY; PHAGOCYTOSIS; TUMOR CELL LINE;

AGED; AGED, 80 AND OVER; ANTIGENS, CD44; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CELL LINE, TUMOR; CELLS, CULTURED; DENDRITIC CELLS; HUMANS; IMMUNITY, INNATE; MIDDLE AGED; PHAGOCYTOSIS; T-LYMPHOCYTES; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 84899482681     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.02.008     Document Type: Article

References (48)

1. Adis International L. Cancer vaccine THERATOPE-Biomira. Drugs R&D 2003, 4:236-240.
2. Almand B., Clark J.I., Nikitina E., van Beynen J., English N.R., Knight S.C., Carbone D.P., Gabrilovich D.I. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J.Immunol. 2001, 166:678-689.
3. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
4. Beatty J.D., Islam S., North M.E., Knight S.C., Ogden C.W. Urine dendritic cells: a noninvasive probe for immune activity in bladder cancer?. BJU Int. 2004, 94:1377-1383.
5. Cao Y., Stosiek P., Springer G.F., Karsten U. Thomsen-Friedenreich-related carbohydrate antigens in normal adult human tissues: a systematic and comparative study. Histochem. Cell Biol. 1996, 106:197-207.
6. Carlos C.A., Dong H.F., Howard O.M., Oppenheim J.J., Hanisch F.G., Finn O.J. Human tumor antigen MUC1 is chemotactic for immature dendritic cells and elicits maturation but does not promote Th1 type immunity. J.Immunol. 2005, 175:1628-1635.
7. Crespo H.J., Cabral M.G., Teixeira A.V., Lau J.T., Trindade H., Videira P.A. Effect of sialic acid loss on dendritic cell maturation. Immunology 2009, 128:e621-e631.
8. Ferreira J.A., Videira P.A., Lima L., Pereira S., Silva M., Carrascal M., Severino P.F., Fernandes E., Almeida A., Costa C., Vitorino R., Amaro T., Oliveira M.J., Reis C.A., Dall'Olio F., Amado F., Santos L.L. Overexpression of tumour-associated carbohydrate antigen sialyl-Tn in advanced bladder tumours. Mol. Oncol. 2013, 7:719-731.
9. + T cell immunity against B16 melanoma. J.Immunol. 2003, 171:5940-5947.
10. Golshani R., Lopez L., Estrella V., Kramer M., Iida N., Lokeshwar V.B. Hyaluronic acid synthase-1 expression regulates bladder cancer growth, invasion, and angiogenesis through CD44. Cancer Res. 2008, 68:483-491.
11. Griffiths A.B., Padmanabhan N., Shepherd P., Lazarus C., Maisey M., Fentiman I., Rubens R., Taylor-Papadimitriou J. Monoclonal antibody HMFG-2 retains activity invivo and binds to high molecular weight components expressed by metastatic breast cancers. Mol. Biol. Med. 1986, 3:425-435.
12. Hegde V.L., Singh N.P., Nagarkatti P.S., Nagarkatti M. CD44 mobilization in allogeneic dendritic cell-T cell immunological synapse plays a key role in T cell activation. J.Leukoc. Biol. 2008, 84:134-142.
13. Heimburg-Molinaro J., Lum M., Vijay G., Jain M., Almogren A., Rittenhouse-Olson K. Cancer vaccines and carbohydrate epitopes. Vaccine 2011, 29:8802-8826.
14. Holmberg L.A., Sandmaier B.M. Vaccination with theratope (STn-KLH) as treatment for breast cancer. Expert Rev. Vaccines 2004, 3:655-663.
15. Ishida A., Ohta M., Toda M., Murata T., Usui T., Akita K., Inoue M., Nakada H. Mucin-induced apoptosis of monocyte-derived dendritic cells during maturation. Proteomics 2008, 8:3342-3349.
16. Itzkowitz S.H., Bloom E.J., Kokal W.A., Modin G., Hakomori S., Kim Y.S. Sialosyl-Tn. A novel mucin antigen associated with prognosis in colorectal cancer patients. Cancer 1990, 66:1960-1966.
17. Jacobs P.P., Sackstein R. CD44 and HCELL: preventing hematogenous metastasis at step 1. FEBS Lett. 2011, 585:3148-3158.
18. Julien S., Adriaenssens E., Ottenberg K., Furlan A., Courtand G., Vercoutter-Edouart A.S., Hanisch F.G., Delannoy P., Le Bourhis X. ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity. Glycobiology 2006, 16:54-64.
19. Julien S., Krzewinski-Recchi M.A., Harduin-Lepers A., Gouyer V., Huet G., Le Bourhis X., Delannoy P. Expression of sialyl-Tn antigen in breast cancer cells transfected with the human CMP-Neu5Ac: GalNAc alpha2,6-sialyltransferase (ST6GalNac I) cDNA. Glycoconj. J. 2001, 18:883-893.
20. Julien S., Picco G., Sewell R., Vercoutter-Edouart A.S., Tarp M., Miles D., Clausen H., Taylor-Papadimitriou J., Burchell J.M. Sialyl-Tn vaccine induces antibody-mediated tumour protection in a relevant murine model. Br. J. Cancer 2009, 100:1746-1754.
21. Julien S., Videira P.A., Delannoy P. Sialyl-Tn in cancer: (how) did we miss the target?. Biomolecules 2012, 2:435-466.
22. Kjeldsen T., Clausen H., Hirohashi S., Ogawa T., Iijima H., Hakomori S. Preparation and characterization of monoclonal antibodies directed to the tumor-associated O-linked sialosyl-2---6 alpha-N-acetylgalactosaminyl (sialosyl-Tn) epitope. Cancer Res. 1988, 48:2214-2220.
23. Lakshminarayanan V., Thompson P., Wolfert M.A., Buskas T., Bradley J.M., Pathangey L.B., Madsen C.S., Cohen P.A., Gendler S.J., Boons G.J. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine. Proc. Natl. Acad. Sci. U S A 2012, 109:261-266.
24. Langenkamp A., Messi M., Lanzavecchia A., Sallusto F. Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat. Immunol. 2000, 1:311-316.
25. Lima L., Severino P.F., Silva M., Miranda A., Tavares A., Pereira S., Fernandes E., Cruz R., Amaro T., Reis C.A., Dall'olio F., Amado F., Videira P.A., Santos L., Ferreira J.A. Response of high-risk of recurrence/progression bladder tumours expressing sialyl-Tn and sialyl-6-T to BCG immunotherapy. Br. J. Cancer 2013, 109:2106-2114.
26. Lin J.C., Liao S.K., Lee E.H., Hung M.S., Sayion Y., Chen H.C., Kang C.C., Huang L.S., Cherng J.M. Molecular events associated with epithelial to mesenchymal transition of nasopharyngeal carcinoma cells in the absence of Epstein-Barr virus genome. J.Biomed. Sci. 2009, 16:105.
27. Madsen C.B., Pedersen A.E., Wandall H.H. Glycan-mediated modification of the immune response. Oncoimmunology 2013, 2:e23659.
28. Marcos N.T., Bennett E.P., Gomes J., Magalhaes A., Gomes C., David L., Dar I., Jeanneau C., DeFrees S., Krustrup D., Vogel L.K., Kure E.H., Burchell J., Taylor-Papadimitriou J., Clausen H., Mandel U., Reis C.A. ST6GalNAc-I controls expression of sialyl-Tn antigen in gastrointestinal tissues. Front. Biosci. 2011, 3:1443-1455.
29. Miles D., Roche H., Martin M., Perren T.J., Cameron D.A., Glaspy J., Dodwell D., Parker J., Mayordomo J., Tres A., Murray J.L., Ibrahim N.K., Theratope Study G. Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist 2011, 16:1092-1100.
30. Monti P., Leone B.E., Zerbi A., Balzano G., Cainarca S., Sordi V., Pontillo M., Mercalli A., Di Carlo V., Allavena P., Piemonti L. Tumor-derived MUC1 mucins interact with differentiating monocytes and induce IL-10highIL-12low regulatory dendritic cell. J.Immunol. 2004, 172:7341-7349.
31. Nair S.K., Snyder D., Rouse B.T., Gilboa E. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. International journal of cancer. J.Int. Cancer 1997, 70:706-715.
32. Niederhafner P., Reinis M., Sebestik J., Jezek J. Glycopeptide dendrimers, part III: a review. Use of glycopeptide dendrimers in immunotherapy and diagnosis of cancer and viral diseases. J.Peptide Science Off. Pub. Eur. Peptide Soc. 2008, 14:556-587.
33. Ogden C.A., Pound J.D., Batth B.K., Owens S., Johannessen I., Wood K., Gregory C.D. Enhanced apoptotic cell clearance capacity and B cell survival factor production by IL-10-activated macrophages: implications for Burkitt's lymphoma. J.Immunol. 2005, 174:3015-3023.
34. Ohta M., Ishida A., Toda M., Akita K., Inoue M., Yamashita K., Watanabe M., Murata T., Usui T., Nakada H. Immunomodulation of monocyte-derived dendritic cells through ligation of tumor-produced mucins to Siglec-9. Biochem. Biophy. Res. Commun. 2010, 402:663-669.
35. Ozaki H., Matsuzaki H., Ando H., Kaji H., Nakanishi H., Ikehara Y., Narimatsu H. Enhancement of metastatic ability by ectopic expression of ST6GalNAcI on a gastric cancer cell line in a mouse model. Clin. Exp. Metastasis 2012, 29:229-238.
36. Padler-Karavani V., Yu H., Cao H., Chokhawala H., Karp F., Varki N., Chen X., Varki A. Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: potential implications for disease. Glycobiology 2008, 18:818-830.
37. Palucka K., Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity 2013, 39:38-48.
38. Pinho S., Marcos N.T., Ferreira B., Carvalho A.S., Oliveira M.J., Santos-Silva F., Harduin-Lepers A., Reis C.A. Biological significance of cancer-associated sialyl-Tn antigen: modulation of malignant phenotype in gastric carcinoma cells. Cancer Lett. 2007, 249:157-170.
39. Salmi M., Karikoski M., Elima K., Rantakari P., Jalkanen S. CD44 binds to macrophage mannose receptor on lymphatic endothelium and supports lymphocyte migration via afferent lymphatics. Circ. Res. 2013, 112:1577-1582.
40. Slovin S.F., Ragupathi G., Fernandez C., Diani M., Jefferson M.P., Wilton A., Kelly W.K., Morris M., Solit D., Clausen H., Livingston P., Scher H.I. A polyvalent vaccine for high-risk prostate patients: "are more antigens better?". Cancer Immunol. Immunother. CII 2007, 56:1921-1930.
41. Steinman R.M., Hawiger D., Nussenzweig M.C. Tolerogenic dendritic cells. Annu. Rev. Immunol. 2003, 21:685-711.
42. Troy A.J., Davidson P.J., Atkinson C.H., Hart D.N. CD1a dendritic cells predominate in transitional cell carcinoma of bladder and kidney but are minimally activated. J.Urol. 1999, 161:1962-1967.
43. Vicari A.P., Caux C., Trinchieri G. Tumour escape from immune surveillance through dendritic cell inactivation. Semin. Cancer Biol. 2002, 12:33-42.
44. Videira P.A., Amado I.F., Crespo H.J., Alguero M.C., Dall'Olio F., Cabral M.G., Trindade H. Surface alpha 2-3- and alpha 2-6-sialylation of human monocytes and derived dendritic cells and its influence on endocytosis. Glycoconj. J. 2008, 25:259-268.
45. Videira P.A., Calais F.M., Correia M., Ligeiro D., Crespo H.J., Calais F., Trindade H. Efficacy of bacille Calmette-Guerin immunotherapy predicted by expression of antigen-presenting molecules and chemokines. Urology 2009, 74:944-950.
46. Videira P.A., Correia M., Malagolini N., Crespo H.J., Ligeiro D., Calais F.M., Trindade H., Dall'Olio F. ST3Gal.I sialyltransferase relevance in bladder cancer tissues and cell lines. BMC Cancer 2009, 9:357.
47. Weiss J.M., Sleeman J., Renkl A.C., Dittmar H., Termeer C.C., Taxis S., Howells N., Hofmann M., Kohler G., Schopf E., Ponta H., Herrlich P., Simon J.C. An essential role for CD44 variant isoforms in epidermal Langerhans cell and blood dendritic cell function. J.Cell Biol. 1997, 137:1137-1147.
48. Werther J.L., Tatematsu M., Klein R., Kurihara M., Kumagai K., Llorens P., Guidugli Neto J., Bodian C., Pertsemlidis D., Yamachika T., Kitou T., Itzkowitz S. Sialosyl-Tn antigen as a marker of gastric cancer progression: an international study. Int. J. Cancer 1996, 69:193-199.